https://www.selleckchem.com/pr....oducts/amredobresib.
50; 95% confidence interval, 1.44-1.57). After considering the amounts of PPIs stratified by cumulative defined daily dose, the dose-response effect was observed until 180days. Subgroup analysis also revealed that PPI use was correlated to an increased risk of fatty liver disease. This current national wide cohort study suggests that PPI use was associated with an increased risk of fatty liver disease compared with non-use of PPIs. Clinicians should consider fatty liver as a potential risk when prescribing PPI. This current nationa
Like
Comment
Share
